Liang Wang1, Tammie L Benzinger1, Jason Hassenstab1, Tyler Blazey1, Christopher Owen1, Jingxia Liu1, Anne M Fagan1, John C Morris1, Beau M Ances2. 1. From the Departments of Neurology (L.W., J.H., T.B., A.M.F., J.C.M., B.M.A.), Radiology (T.L.B., C.O., B.M.A.), Psychology (J.H.), and Neurosurgery (T.L.B.), The Charles F. and Joanne Knight Alzheimer's Disease Research Center (T.L.B., J.H., A.M.F., J.C.M., B.M.A.), The Hope Center for Neurological Disorders (A.M.F., J.C.M., B.M.A.), and Division of Biostatistics (J.L.), Washington University in Saint Louis, MO. 2. From the Departments of Neurology (L.W., J.H., T.B., A.M.F., J.C.M., B.M.A.), Radiology (T.L.B., C.O., B.M.A.), Psychology (J.H.), and Neurosurgery (T.L.B.), The Charles F. and Joanne Knight Alzheimer's Disease Research Center (T.L.B., J.H., A.M.F., J.C.M., B.M.A.), The Hope Center for Neurological Disorders (A.M.F., J.C.M., B.M.A.), and Division of Biostatistics (J.L.), Washington University in Saint Louis, MO. bances@wustl.edu.
Abstract
OBJECTIVES: To determine whether an MRI-based Alzheimer disease (AD) signature biomarker can detect tau-related neurodegeneration in preclinical AD, and to assess whether AD signature cortical thinning is associated with cognitive changes in cognitively normal (CN) older individuals. METHODS: In a large cohort of CN individuals (n = 188), we measured the hippocampal volume and cortical thickness within independently defined AD signature regions. We cross-sectionally assessed the associations between AD signature cortical thinning or hippocampal atrophy with CSF biomarkers of tau (increased tau) and β-amyloid (Aβ) (decreased Aβ42). We also examined the impact of AD signature cortical thinning or other biomarker changes (i.e., hippocampal atrophy, reduced CSF Aβ42, or increased CSF tau) on cognitive performance in CN individuals. RESULTS: Elevated CSF tau was associated with AD signature cortical thinning but not hippocampal atrophy. In contrast, decreased CSF Aβ42 was associated with hippocampal loss but not AD signature cortical thinning. In addition, AD signature cortical thinning was associated with lower visuospatial performance. Reduced CSF Aβ42 was related to poorer performance on episodic memory. CONCLUSIONS: Spatially distinct neurodegeneration is associated with Aβ and tau pathology in preclinical AD. Aβ deposition and AD signature cortical atrophy independently affect cognition in CN older individuals.
OBJECTIVES: To determine whether an MRI-based Alzheimer disease (AD) signature biomarker can detect tau-related neurodegeneration in preclinical AD, and to assess whether AD signature cortical thinning is associated with cognitive changes in cognitively normal (CN) older individuals. METHODS: In a large cohort of CN individuals (n = 188), we measured the hippocampal volume and cortical thickness within independently defined AD signature regions. We cross-sectionally assessed the associations between AD signature cortical thinning or hippocampal atrophy with CSF biomarkers of tau (increased tau) and β-amyloid (Aβ) (decreased Aβ42). We also examined the impact of AD signature cortical thinning or other biomarker changes (i.e., hippocampal atrophy, reduced CSF Aβ42, or increased CSF tau) on cognitive performance in CN individuals. RESULTS: Elevated CSF tau was associated with AD signature cortical thinning but not hippocampal atrophy. In contrast, decreased CSF Aβ42 was associated with hippocampal loss but not AD signature cortical thinning. In addition, AD signature cortical thinning was associated with lower visuospatial performance. Reduced CSF Aβ42 was related to poorer performance on episodic memory. CONCLUSIONS: Spatially distinct neurodegeneration is associated with Aβ and tau pathology in preclinical AD. Aβ deposition and AD signature cortical atrophy independently affect cognition in CN older individuals.
Authors: Bruce Fischl; David H Salat; Evelina Busa; Marilyn Albert; Megan Dieterich; Christian Haselgrove; Andre van der Kouwe; Ron Killiany; David Kennedy; Shuna Klaveness; Albert Montillo; Nikos Makris; Bruce Rosen; Anders M Dale Journal: Neuron Date: 2002-01-31 Impact factor: 17.173
Authors: David S Knopman; Clifford R Jack; Heather J Wiste; Stephen D Weigand; Prashanthi Vemuri; Val J Lowe; Kejal Kantarci; Jeffrey L Gunter; Matthew L Senjem; Michelle M Mielke; Rosebud O Roberts; Bradley F Boeve; Ronald C Petersen Journal: Ann Neurol Date: 2013-02-19 Impact factor: 10.422
Authors: Miranka Wirth; Cindee M Madison; Gil D Rabinovici; Hwamee Oh; Susan M Landau; William J Jagust Journal: J Neurosci Date: 2013-03-27 Impact factor: 6.167
Authors: Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters Journal: Lancet Neurol Date: 2013-03-08 Impact factor: 44.182
Authors: Prashanthi Vemuri; Jennifer L Whitwell; Kejal Kantarci; Keith A Josephs; Joseph E Parisi; Maria S Shiung; David S Knopman; Bradley F Boeve; Ronald C Petersen; Dennis W Dickson; Clifford R Jack Journal: Neuroimage Date: 2008-05-20 Impact factor: 6.556
Authors: Jan P Vandenbroucke; Erik von Elm; Douglas G Altman; Peter C Gøtzsche; Cynthia D Mulrow; Stuart J Pocock; Charles Poole; James J Schlesselman; Matthias Egger Journal: PLoS Med Date: 2007-10-16 Impact factor: 11.069
Authors: Brenna Cholerton; Adam Omidpanah; Tara M Madhyastha; Thomas J Grabowski; Astrid M Suchy-Dicey; Dean K Shibata; Lonnie A Nelson; Steven P Verney; Barbara V Howard; William T Longstreth; Thomas J Montine; Dedra Buchwald Journal: Alzheimer Dis Assoc Disord Date: 2017 Apr-Jun Impact factor: 2.703
Authors: Peter R Millar; Beau M Ances; Brian A Gordon; Tammie L S Benzinger; Anne M Fagan; John C Morris; David A Balota Journal: Neurobiol Aging Date: 2020-08-18 Impact factor: 4.673
Authors: Samantha L Allison; Thomas L Rodebaugh; Chiharu Johnston; Anne M Fagan; John C Morris; Denise Head Journal: Arch Clin Neuropsychol Date: 2019-10-24 Impact factor: 2.813
Authors: Marina Buciuc; Alexandra M Wennberg; Stephen D Weigand; Melissa E Murray; Matthew L Senjem; Anthony J Spychalla; Bradley F Boeve; David S Knopman; Clifford R Jack; Kejal Kantarci; Joseph E Parisi; Dennis W Dickson; Ronald C Petersen; Jennifer L Whitwell; Keith A Josephs Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Molly R LaPoint; Jasmeer P Chhatwal; Jorge Sepulcre; Keith A Johnson; Reisa A Sperling; Aaron P Schultz Journal: Neuroimage Date: 2017-05-22 Impact factor: 6.556
Authors: Liang Wang; Tammie L Benzinger; Yi Su; Jon Christensen; Karl Friedrichsen; Patricia Aldea; Jonathan McConathy; Nigel J Cairns; Anne M Fagan; John C Morris; Beau M Ances Journal: JAMA Neurol Date: 2016-09-01 Impact factor: 18.302
Authors: Julie K Wisch; Catherine M Roe; Ganesh M Babulal; Suzanne E Schindler; Anne M Fagan; Tammie L Benzinger; John C Morris; Beau M Ances Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Andrew J Aschenbrenner; Brian A Gordon; Tammie L S Benzinger; John C Morris; Jason J Hassenstab Journal: Neurology Date: 2018-08-01 Impact factor: 9.910
Authors: Brian A Gordon; Tyler Blazey; Yi Su; Anne M Fagan; David M Holtzman; John C Morris; Tammie L S Benzinger Journal: JAMA Neurol Date: 2016-10-01 Impact factor: 18.302